Early Study Finds New Lymphoma Drug Effective

May 13, 2022

 • 

Read time:

5-15 mins
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Screen Shot 2022 05 06 At 4.32.40 PM
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Presented by Health Lab

Michigan Health Lab releases an article to talk about a new study regarding a new drug. In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma, a cancer that begins in the lymphatic system, the tissues and organs that produce and store white blood cells. Tycel Phillips, M.D., a hematologist at the Rogel Cancer Center, a clinical associate professor at the University of Michigan Medical School and the lead author of the study discusses the treatment options and how to have better disease control to fight this type of cancer.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.